A major challenge in breast cancer treatment is the cardiotoxicity linked to traditional therapies, especially HER2-targeted drugs like trastuzumab, which, despite their efficacy against HER2-positive breast cancer, can cause congestive heart failure (CHF) [13]. This evidence concerns the gene ERBB2 and breast carcinoma.